Michael Higgins
Stock Analyst at Ladenburg Thalmann
(0.68)
# 2,904
Out of 4,479 analysts
22
Total ratings
25%
Success rate
-12.09%
Average return
Main Sectors:
12 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VRDN Viridian Therapeutics | Downgrades: Neutral | n/a | $12.16 | - | 4 | May 9, 2024 | |
| FBRX Forte Biosciences | Upgrades: Buy | $2.75 | $0.52 | +424.91% | 2 | Apr 8, 2024 | |
| MRNS Marinus Pharmaceuticals | Maintains: Buy | $17 → $13 | $1.19 | +992.44% | 1 | Aug 11, 2023 | |
| OVID Ovid Therapeutics | Reiterates: Buy | $7 | $0.77 | +805.09% | 1 | May 2, 2023 | |
| SCYX SCYNEXIS | Reiterates: Buy | $15 | $1.95 | +669.23% | 1 | Apr 3, 2023 | |
| ARTL Artelo Biosciences | Reiterates: Buy | $60 | $1.32 | +4,445.45% | 2 | Apr 3, 2023 | |
| RYTM Rhythm Pharmaceuticals | Reiterates: Buy | $35 | $42.34 | -17.34% | 3 | Mar 2, 2023 | |
| PTN Palatin Technologies | Maintains: Buy | $2 → $50 | $1.88 | +2,559.57% | 1 | Sep 9, 2022 | |
| PHGE BiomX | Maintains: Buy | $13 → $8 | $0.35 | +2,175.31% | 2 | May 12, 2022 | |
| NVAX Novavax | Downgrades: Sell | n/a | $12.97 | - | 2 | Aug 5, 2020 | |
| VIRT Virtu Financial | Upgrades: Buy | n/a | $22.16 | - | 2 | Jan 4, 2019 | |
| SVRA Savara | Reinstates: Buy | n/a | $4.30 | - | 1 | Sep 27, 2017 |
Viridian Therapeutics
May 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $12.16
Upside: -
Forte Biosciences
Apr 8, 2024
Upgrades: Buy
Price Target: $2.75
Current: $0.52
Upside: +424.91%
Marinus Pharmaceuticals
Aug 11, 2023
Maintains: Buy
Price Target: $17 → $13
Current: $1.19
Upside: +992.44%
Ovid Therapeutics
May 2, 2023
Reiterates: Buy
Price Target: $7
Current: $0.77
Upside: +805.09%
SCYNEXIS
Apr 3, 2023
Reiterates: Buy
Price Target: $15
Current: $1.95
Upside: +669.23%
Artelo Biosciences
Apr 3, 2023
Reiterates: Buy
Price Target: $60
Current: $1.32
Upside: +4,445.45%
Rhythm Pharmaceuticals
Mar 2, 2023
Reiterates: Buy
Price Target: $35
Current: $42.34
Upside: -17.34%
Palatin Technologies
Sep 9, 2022
Maintains: Buy
Price Target: $2 → $50
Current: $1.88
Upside: +2,559.57%
BiomX
May 12, 2022
Maintains: Buy
Price Target: $13 → $8
Current: $0.35
Upside: +2,175.31%
Novavax
Aug 5, 2020
Downgrades: Sell
Price Target: n/a
Current: $12.97
Upside: -
Virtu Financial
Jan 4, 2019
Upgrades: Buy
Price Target: n/a
Current: $22.16
Upside: -
Savara
Sep 27, 2017
Reinstates: Buy
Price Target: n/a
Current: $4.30
Upside: -